Xenon Pharmaceuticals Inc
F:XP0
Net Margin
Xenon Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
2.3B USD |
-3 353%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
336.1B USD |
7%
|
|
| US |
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 848%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.8B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
144.7B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.7B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
129.7B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.9B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Xenon Pharmaceuticals Inc
Glance View
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company spotlighted in the arena of precision medicine, with a strategic emphasis on neurological disorders. The company finds its roots in the ethos of innovation, aiming to transform the landscape of treatment through the development of novel therapeutics. At the heart of its operations is a robust platform driven by genetic insights, which allows the company to unearth underlying neurological pathways, thereby targeting diseases that truly lack effective treatment options. Xenon leverages its deep expertise in ion channel biology—vastly important in the function of the nervous system—to design small molecule therapies, positioning itself as a pioneer in addressing complex cerebral disorders such as epilepsy. A key aspect of how Xenon Pharmaceuticals generates revenue is through a dual approach: self-initiated proprietary product development and strategic collaborations with established pharmaceutical giants. Its revenue model is largely propelled by both developmental milestone payments and potential royalties from these alliances. This includes partnerships that allow Xenon to share its innovative platform while receiving financial backing and resources, ensuring the infrastructural strength needed to sustain its clinical programs. By maintaining a pipeline that promises targeted, personalized treatments, Xenon aims not only to meet clinical milestones but to also carve out significant market share within the neuroscience domain, paving its path to profitability and industry impact.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Xenon Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -3 352.6%.
You don't have any saved screeners yet